Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results.
For best results when printing this announcement, please click on link below: Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1(st) — September 30, 2026) Regulatory News: Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial re
For best results when printing this announcement, please click on link below: Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan Since July 2026, Medincell has secured €41.8 million in non-dilutive financing, repaid 50% of its European Investment
Teva said the FDA approved Weltruza, a once-monthly injectable treatment for schizophrenia. The company said it is the first under-the-skin shot of its kind for the disease.
Trading in Medincell shares on Euronext Paris is set to resume at 2:45 p.m. CEST after a company-requested suspension earlier today pending a press release.
Medincell said its partner Teva announced U.S. FDA approval of WELTRUZA, an extended-release injectable suspension of olanzapine for adults with schizophrenia. Teva plans to make the treatment available in the United States in the coming weeks.
Teva announced U.S. FDA approval of WELTRUZA™ (olanzapine) for extended-release injectable suspension, described as a once-monthly subcutaneous injectable for adults with schizophrenia.